A Pharmacist may prescribe, via statewide drug therapy management protocol and according to rules outlined in this Division, an FDA-approved drug and device listed in the following compendium:
(1) Continuation of therapy including emergency refills of insulin (v. 06/2023)(2) Conditions (a) Cough and cold symptom management (A) Pseudoephedrine (v. 06/2021);(B) Benzonatate (v. 06/2021);(C) Short-acting beta agonists (v. 06/2021);(D) Intranasal corticosteroids (v. 06/2021);(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);(c) COVID-19 Antigen Self-Test (v. 12/2021);(3) Preventative care (a) Emergency Contraception (v. 06/2021);(b) Male and female condoms (v. 06/2021);(c) Tobacco Cessation, Nicotine Replacement Therapy (NRT) and Non-NRT (v. 06/2022);(d) Travel Medications (v. 06/2023);(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023);(g) Contraception (v. 06/2023); and(h) Vaccinations: (A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 2/2024);(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 2/2024);(D) Coronavirus 2019 (v. 2/2024);(E) Haemophilus Influenza type b (v. 2/2024)(F) Hepatitis A containing vaccines (v. 2/2024);(G) Hepatitis B containing vaccines (v. 2/2024);(H) Human Papillomavirus (v. 2/2024);(I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 2/2024);(J) Influenza - Live Attenuated Influenza Vaccine 2023-24 (v. 2/2024);(K) Japanese Encephalitis (v. 2/2024);(L) Meningococcal containing vaccines (v. 2/2024);(M) Measles Mumps & Rubella containing vaccines (v. 2/2024);(N) Pneumococcal (v. 2/2024);(Q) Respiratory Syncytial Virus (v. 2/2024);(R) Tetanus Diphtheria containing vaccines (v. 2/2024);(T) Varicella containing vaccines (v. 2/2024);(U) Yellow fever (v. 2/2024);Or. Admin. R. 855-020-0300
BP 5-2018, adopt filed 10/18/2018, effective 10/18/2018; BP 7-2019, amend filed 10/15/2019, effective 10/16/2019; BP 85-2020, amend filed 08/26/2020, effective 8/27/2020; BP 96-2020, amend filed 12/23/2020, effective 12/23/2020; BP 18-2021, amend filed 06/15/2021, effective 6/15/2021; BP 22-2021, temporary amend filed 09/01/2021, effective 9/1/2021 through 2/27/2022; BP 31-2021, amend filed 12/10/2021, effective 12/10/2021; BP 34-2021, temporary amend filed 12/10/2021, effective 12/10/2021through 6/7/2022; BP 16-2022, amend filed 04/20/2022, effective 4/20/2022; BP 31-2022, amend filed 06/15/2022, effective 6/16/2022; BP 44-2022, temporary amend filed 10/17/2022, effective 10/17/2022 through 4/14/2023; BP 56-2022, amend filed 12/20/2022, effective 2/1/2023; BP 4-2023, temporary amend filed 02/10/2023, effective 2/10/2023through 8/8/2023; BP 11-2023, amend filed 06/13/2023, effective 6/13/2023; BP 33-2023, amend filed 12/19/2023, effective 2/1/2024; BP 1-2024, temporary suspend filed 02/15/2024, effective 2/29/2024 through 8/26/2024Publications referenced are available from the agency.
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689 & ORS 689.696